January 05, 2010
Majority of Neurologists need more long-term safety data before prescribing oral MS agents as first line therapy
Cambridge, MA — SERMO, the world’s largest online community for physicians, today announced a new SERMO Event™ Report assessing physician perception of FDA’s “refuse to file” (RTF) letter on EMD Serono’s Cladribine tablets and its potential impact, if any, on Novartis’ oral MS agent in development; Fingolimod. Cladribine is expected to be one of the first oral agents to be approved for the treatment of relapsing and remitting multiple sclerosis.
According to the findings, most Neurologists are anxious for an oral MS agent and believe Cladribine will ultimately be approved. Physicians also indicate that patients are eagerly awaiting an oral agent even if it comes with higher side effects. However, the majority of Neurologists express the need for more long-term safety data and are apprehensive to increase adoption after deaths from PML associated with Tysabri.
SERMO Event Reports rapidly assess physician reaction to major events impacting the US pharmaceutical market. The new report titled “Cladribine/Fingolimod: Estimating the Impact of Oral MS Agents” polled 300 US Neurologists. All respondents are verified and credentialed, ensuring they have valid, active licenses to practice medicine in the United States. Reports are available for purchase at http://www.SERMO.com/business-solutions or by calling 877-778-3963.
SERMO is the largest online physician community in the US. It’s where over 110,000 practicing physicians collaborate on difficult cases and exchange observations about drugs, devices and clinical issues. Through a unique set of social media tools, SERMO provides access to its community for organizations that need fast, actionable MD insights into treatments, drugs and devices. Visit http://www.SERMO.com to learn more.